Avastin plus chemotherapy receives positive recommendation from CHMP for EU approval

Roche announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the use of Avastin® (bevacizumab) in combination with standard chemotherapy (paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy) for the treatment of adult patients with persistent, recurrent or metastatic carcinoma of the cervix. Cervical cancer is most commonly diagnosed in younger women, those between the ages of 35 and 44, and every year over 30,000 women in the EU are diagnosed with the disease.